AbbVie Inc

AbbVie (ABBV) generated net revenue of $7.9 billion in 1Q18 compared to $6.5 billion in 1Q17.

Adage Capital added a new position in Mallinckrodt Plc (MNK) in the third quarter of 2014. The position accounted for 0.82% of the fund’s total portfolio.

Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.

As part of its significant product line extension, Gilead Sciences (GILD) is entering therapeutic areas such as oncology, pulmonology, and cardiology.

In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

A major reason for the Pharmacyclics–AbbVie merger is to diversify AbbVie away from its reliance on a single product, Humira, and boost its pipeline.

In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.

Here we present an overview of BioMarin. It’s based in California and was founded in 1997. It focuses on therapies for life-threatening rare genetic diseases.

In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.

On September 20, Mylan and its partner, Fujifilm Kyowa Kirin Biologics, received the marketing authorization from the European Commission for Hulio.

YTD, Amgen’s (AMGN) stock has already fallen 9%. Perhaps the pressure that Enbrel (etanercept) is seeing is to blame for the negative investor sentiment.

In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.

In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis.

In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).

Abbott Laboratories (ABT) is a brand new position that accounts for 1.19% of Chilton’s fourth quarter 2013 portfolio.

Adage Capital’s US long portfolio grew from $38.69 billion in 2Q14 to $40.2 billion in 3Q14. The portfolio comprised around 699 stocks.

Maverick Capital lowered its position in Baidu, Inc. in 3Q14. The position accounts for 0.36% of the fund’s total portfolio in the third quarter.

AbbVie (ABBV) is currently evaluating more than 20 investigational therapies targeting solid tumors. Seventeen of them are in Phase 1 trials.

AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.

In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.

On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.

Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

Only 525,000 patients (or 55% of the diagnosed psoriatic arthritis patients) were eligible for treatment with biologics.

According to Novartis’s estimates for the US biologics market in 2016, there were ~8.4 million patients with moderate to severe psoriasis in the US.

In 4Q17, Amgen’s (AMGN) Neulasta generated revenues of $1.1 billion, which reflected a 1% decline on a quarter-over-quarter basis.

In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) subsidiary Sandoz generated revenues of $2.4 billion, $2.5 billion, and $2.6 billion, respectively.

On January 22, Vermont decriminalized the possession of marijuana for adults 21 and older. Vermont became the ninth state to legalize marijuana for recreational purposes.

Given that legislative approval is the strongest driving factor behind the boost in the marijuana industry, companies have rushed to capitalize on the wave.

In the previous part of this series, we saw that the alcohol industry could expect marijuana legalization for recreational purposes as an extension to their growth strategy.

Analysts expect Novartis’s revenues to rise ~3.9% to $12.8 billion in 4Q17, driven by growth in operating revenues across all three segments.

It’s fascinating to see how the marijuana landscape around the world has evolved in the last three years. According to Canopy Growth (WEED.TO), Canada, Israel, the Czech Republic, Uruguay, and the Netherlands “established federally legal cannabis access regimes” in 2014.

In 1Q17, 2Q17, and 3Q17, Amgen’s (AMGN) Enbrel generated revenues of ~$1.2 billion, ~$1.5 billion, and ~$1.4 billion, respectively.

On December 20, 2017, AbbVie (ABBV) reported positive top-line results from its phase-3 trial Select-Monotherapy.

In September 2017, AbbVie’s (ABBV) investigational immunology drug, Upadacitinib (ABT-494), managed to demonstrate its clinical potential.

In 3Q17, Johnson & Johnson’s (JNJ) Remicade generated revenues of $1.6 billion, which reflected a ~8% decline on a year-over-year (or YoY) basis and 8% growth on a quarter-over-quarter basis.

Immunology drug revenue In 3Q17, Remicade generated revenue of $214 million, a ~31% fall YoY (year-over-year) and 3% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Remicade reported revenue of $651 million, which reflected a ~35% fall YoY. Foreign exchange had a 3% favorable effect towards 3Q17 Remicade revenue. In 3Q17, Simponi reported revenue of […]

Sanofi reports its business in two segments: Human Pharmaceuticals and Sanofi Pasteur, or the Human Vaccines segment.

In 3Q17, AbbVie’s (ABBV) Lupron generated revenues of around $201 million, which reflected ~4% growth on a year-over-year (or YoY) basis.

In September 2017, AbbVie (ABBV) presented successful results from its phase 3 SELECT-BEYOND trial.

In September 2017, AbbVie (ABBV) presented the results from a phase 2B trial of upadacitinib (ABT-494) for the treatment of adult individuals with moderate to severe atopic dermatitis.

In the first half of 2017, Roche’s (RHHBY) Xolair reported revenues of CHF 866.0 million, which is a 17.0% rise on a YoY (year-over-year) basis.

In 1H17, Novartis’s (NVS) Cosentyx generated revenues of around $900 million compared to $436 million in 1H16.

In 1H17, Novartis (NVS) reported revenues of around $23.8 billion, a ~1% decline on a year-over-year (or YoY) basis.

Regeneron and Sanofi have submitted an application seeking regulatory approval for Kevzara in Japan.

In August 2017, JAZZ’s Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.

On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.

Medtronics’ MITG (Minimally Invasive Therapies Group) business is expected to grow 3.5%–4.5%.

In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.